L
Lei Shen
Researcher at Eli Lilly and Company
Publications - 18
Citations - 7360
Lei Shen is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Clopidogrel & Prasugrel. The author has an hindex of 12, co-authored 16 publications receiving 6065 citations.
Papers
More filters
Journal ArticleDOI
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Jessica L. Mega,Sandra L Close,Stephen D. Wiviott,Lei Shen,Richard D. Hockett,John T. Brandt,Joseph R. Walker,Elliott M. Antman,William L. Macias,Eugene Braunwald,Marc S. Sabatine +10 more
TL;DR: Carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major adverse cardiovascular events, including stent thrombosis, than did noncarriers.
Journal ArticleDOI
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
Peter Chen,Ajay Nirula,Barry Heller,Robert L. Gottlieb,Joseph Boscia,Jason Morris,Gregory D. Huhn,Jose Cardona,Bharat Mocherla,Valentina Stosor,Imad Shawa,Andrew C. Adams,Jacob Van Naarden,Kenneth L. Custer,Lei Shen,Michael Durante,Gerard J. Oakley,Andrew E. Schade,Janelle Sabo,Dipak R. Patel,Paul Klekotka,Daniel Skovronsky +21 more
TL;DR: In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11.
Journal ArticleDOI
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Jessica L. Mega,Tabassome Simon,Jean-Philippe Collet,Jeffrey L. Anderson,Elliott M. Antman,Kevin P. Bliden,Christopher P. Cannon,Nicolas Danchin,Betti Giusti,Paul A. Gurbel,Benjamin D. Horne,Jean Sebastian Hulot,Adnan Kastrati,Gilles Montalescot,Franz-Josef Neumann,Lei Shen,Dirk Sibbing,P. Gabriel Steg,Dietmar Trenk,Stephen D. Wiviott,Marc S. Sabatine +20 more
TL;DR: Among patients treated with clopidogrel for percutaneous coronary intervention, carriage of even 1 reduced-function CYP2C19 allele appears to be associated with a significantly increased risk of major adverse cardiovascular events, particularly stent thrombosis.
Journal ArticleDOI
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Robert L. Gottlieb,Ajay Nirula,Peter Chen,Joseph Boscia,Barry Heller,Jason Morris,Gregory D. Huhn,Jose Cardona,Bharat Mocherla,Valentina Stosor,Imad Shawa,Princy Kumar,Andrew C. Adams,Jacob Van Naarden,Kenneth L. Custer,Michael Durante,Gerard J. Oakley,Andrew E. Schade,Timothy R. Holzer,Philip J. Ebert,Richard E. Higgs,Nicole L. Kallewaard,Janelle Sabo,Dipak R. Patel,Paul Klekotka,Lei Shen,Daniel Skovronsky +26 more
TL;DR: The BLAZE-1 trial as mentioned in this paper evaluated the effect of bamlanivimab monotherapy and combination therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild to moderate COVID-19.
Journal ArticleDOI
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
Michelle L. O'Donoghue,Eugene Braunwald,Elliott M. Antman,Sabina A. Murphy,Eric R. Bates,Yoseph Rozenman,Alan D. Michelson,Raymond W Hautvast,Peter N. Lee,Sandra L Close,Lei Shen,Jessica L. Mega,Marc S. Sabatine,Stephen D. Wiviott +13 more
TL;DR: The current findings do not support the need to avoid concomitant use of PPIs, when clinically indicated, in patients receiving clopidogrel or prasugrel.